Alivus Life Sciences Investor Presentation for Q2 FY26
Alivus Life Sciences announced its investor presentation for Q2 FY26, reporting revenue of ₹5,880 million, a growth of 16% YoY. EBITDA stood at ₹1,939 million with a margin of 33%.
The results indicate a positive trajectory for the company, which could be of interest to investors. The growth in key business segments and strong financial performance contribute to a medium impact.
The announcement highlights positive financial results including revenue growth, strong EBITDA margins, and healthy cash flow. The management commentary is also optimistic.
* Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) announced its investor presentation for Q2 FY26. * Revenue from operations was ₹5,880 million for Q2 FY26, a growth of 16% YoY. * EBITDA for the quarter stood at ₹1,939 million with a margin of 33%, up by 480 bps YoY. * PAT for the quarter was ₹1,301 million. * Generic API revenues in Q2 FY26 grew by 15.3% YoY, and CDMO revenues grew by 15.8% YoY. * GPL business was at ₹1,437 million, a de-growth of 23.9% YoY due to inventory rationalization at the customer’s end. Non-GPL business was at ₹4,443 million, up by 39.7% YoY. * The company generated a free cash flow of ₹1,477 million during Q2 FY26, leading to cash and cash equivalents (including short term investments) of ₹6,526 million as of 30th September 2025. * Dr. Yasir Rawjee, Managing Director & Chief Executive Officer, commented that the company's performance was fuelled by strong momentum in the non-GPL business, which delivered an impressive 39.7% YoY growth. He also mentioned the company remains confident of maintaining margins at around 30%, despite the absence of PLI benefits.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.